Montaño ELF, Fortoul VGTI, Rendón HEP

Language: Spanish
References: 27
Page: 42-49
PDF size: 765.63 Kb.

ABSTRACT

One highly common medical malpractice is the undiscriminatory use of inflammation inhibiting drugs. Inflammation is a biological repair process vastly controlled by intracellular complexes known as the inflammasome that act as sensors and mediators of the inflammation process. Inflammasomes are members of the NOD innate immune system family of receptors that consist of 3 closely related subfamilies: nucleotide- binding oligomerization domain (NOD), NOD-like receptor CARD domain containing (NLRC), and NOD-like receptor Pyrin domain containing (NLRP); the latter is the most directly related to the inflammasome. There are 14 dif-ferent NLRPs all of which are activated by exogenous signals through pathogen-associated molecular patterns (PAMPs) or by endogenous signals via damage-associated molecular patterns, also known as alarmins, are endogenous molecules constitutively available and released upon tissue damage (DAMPs). Once activated, the components of the NLRP inflammasome begin an assembling process that follows a pre-established pattern so a caspase-1 activating complex is formed. This complex activates IL-1b, IL-18 and IL-33 precursors thus favoring the secretion of this cytokines to the extracellular milieu. IL-1 and IL-18 are members of the same cytokine family and their main function is to regulate the innate and adaptive immune response whereas IL-33, also a member of the IL-1 family of cytokines, is considered an alarmin. We emphasize the structure and formation of NLRP3, implicated on a host of inflammatory disorders, with special attention to its participation in Alzheimer´s diseases.

REFERENCES

1. Guo H, Callaway JB, Ting JP. Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med. 2015;21(7):677-87.

2. Schroder K, Tschopp J. The inflammasomes. Cell. 2010; 140(6):821-32.

3. Latz E. The inflammasomes: mechanisms of activation and function. Curr Opin Immunol. 2010;22(1):28-33.

4. Chavarria-Smith J, Vance RE. The NLRP1 inflammasomes. Immunol Rev. 2015;265(1):22-34.

5. He Y, Franchi L, Nunez G. TLR agonists stimulate Nlrp3- dependent IL-1beta production independently of the purinergic P2X7 receptor in dendritic cells and in vivo. J Immunol. 2013;190(1):334-9.

6. Keyel PA. How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1. Cytokine. 2014;69(1):136-45.

7. Craven RR, Gao X, Allen IC, Gris D, Bubeck Wardenburg J, McElvania-Tekippe E, et al. Staphylococcus aureus alpha-hemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells. PLoS One. 2009; 4(10):e7446.

8. Vance RE. The NAIP/NLRC4 inflammasomes. Curr Opin Immunol. 2015;32:84-9.

9. Cayrol C, Girard JP. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci USA. 2009;106(22):9021-6.

10. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, Mac- Donald K, Speert D, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. 2009;183(2):787-91.

11. Vajjhala PR, Mirams RE, Hill JM. Multiple binding sites on the pyrin domain of ASC protein allow self-association and interaction with NLRP3 protein. J Biol Chem. 2012;287(50):41732-43.

12. Lu A, Wu H. Structural mechanisms of inflammasome assembly. FEBS J. 2015;282(3):435-44.

13. Shao BZ, Xu ZQ, Han BZ, Su DF, Liu C. NLRP3 inflammasome and its inhibitors: a review. Front Pharmacol. 2015;6:262.

14. Pedra JH, Cassel SL, Sutterwala FS. Sensing pathogens and danger signals by the inflammasome. Curr Opin Immunol. 2009;21(1):10-6.

15. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005;5(4):331-42.

16. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, Mc- Clanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479-90.

17. Zhao W, Hu Z. The enigmatic processing and secretion of interleukin-33. Cell Mol Immunol. 2010;7(4):260-2.

18. Baroja-Mazo A, Martin-Sanchez F, Gomez AI, Martinez CM, Amores-Iniesta J, Compan V, et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol. 2014; 15(8):738-48.

19. Altaf A, Qu P, Zhao Y, Wang H, Lou D, Niu N. NLRP3 inflammasome in peripheral blood monocytes of acute coronary syndrome patients and its relationship with statins. Coron Artery Dis. 2015;26(5):409-21.

20. Yang J, Zhao Y, Shao F. Non-canonical activation of inflammatory caspases by cytosolic LPS in innate immunity. Curr Opin Immunol. 2015;32:78-83.

21. Dorfleutner A, Chu L, Stehlik C. Inhibiting the inflammasome: one domain at a time. Immunol Rev. 2015;265(1):205-16.

22. Lupfer C, Kanneganti TD. Unsolved Mysteries in NLR Biology. Front Immunol. 2013;4:285.

23. Lamkanfi M, Dixit VM. Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol. 2012;28:137-61.

24. Halle A, Hornung V, Petzold GC, Stewart CR, Monks BG, Reinheckel T, et al. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat Immunol. 2008;9(8):857-65.

25. Higashimori A, Watanabe T, Nadatani Y, Takeda S, Otani K, Tanigawa T, et al. Mechanisms of NLRP3 inflammasome activation and its role in NSAID-induced enteropathy. Mucosal Immunol. 2016;9(3):659-68.

26. Hook VY, Kindy M, Hook G. Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, beta-secretase site of the amyloid precursor protein. J Biol Chem. 2008;283(12):7745-53.

27. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, et al. NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice. Nature. 2013;493(7434):674-8.